Skip to main
BCYC
BCYC logo

BCYC Stock Forecast & Price Target

BCYC Analyst Ratings

Based on 17 analyst ratings
Buy
Strong Buy 35%
Buy 47%
Hold 18%
Sell 0%
Strong Sell 0%

Bulls say

Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company with a strong focus on oncology and innovative treatments through its synthetic Bicycle technology, demonstrating promising early Phase 1 results for the product candidate BT8009 that suggest a favorable probability of success. The company's advanced clinical assets, BT8009 and BT5528, have exhibited encouraging efficacy and acceptable safety profiles in treating urothelial and ovarian cancers, indicating potential market viability. Additionally, the robust enrollment rates in clinical trials for the Duravelo-2 study reflect positive momentum, underscoring the company's ability to attract interest and support for its innovative therapies in high unmet medical need areas.

Bears say

Bicycle Therapeutics PLC faces significant challenges that contribute to a negative outlook for its stock. Key financial concerns include the potential 0% success rate for its product candidate, BT8009, which would substantially diminish the company's platform value, and recent lackluster Phase 1 clinical trial data for its oncology indications. Additionally, higher-than-anticipated SG&A expenses and the inherent risks associated with the development of novel therapeutics further complicate Bicycle's financial stability and may lead to diminished investor confidence, even if short-term expectations are met.

BCYC has been analyzed by 17 analysts, with a consensus rating of Buy. 35% of analysts recommend a Strong Buy, 47% recommend Buy, 18% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Bicycle Therapeutics Plc - ADR and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Bicycle Therapeutics Plc - ADR (BCYC) Forecast

Analysts have given BCYC a Buy based on their latest research and market trends.

According to 17 analysts, BCYC has a Buy consensus rating as of Jun 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $32, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $32, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Bicycle Therapeutics Plc - ADR (BCYC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.